VJHemOnc is committed to improving our service to you

ASH 2019 | Dual ABL1 inhibition in elderly ALL: asciminib, dasatinib, prednisone

VJHemOnc is committed to improving our service to you

Daniel DeAngelo

Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the phase 1 study (NCT02081378) of asciminib plus dasatinib and prednisone for untreated BCR-ABL1 positive acute lymphoblastic leukemia (ALL) in older adults. Dual ABL1 kinase inhibition with these agents was promising, and an expansion cohort is planned to further characterize safety and clinical activity of the combination. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter